FISCAL NOTE

Date Requested: February 13, 2021
Time Requested: 11:57 AM
Agency: Insurance Commission
CBD Number: Version: Bill Number: Resolution Number:
2529 Introduced SB233
CBD Subject: State Personnel


FUND(S):

7152 OIC Operating Fund

Sources of Revenue:

Special Fund

Legislation creates:





Fiscal Note Summary


Effect this measure will have on costs and revenues of state government.


Senate Bill 233, if enacted, would have no fiscal impact on the Offices of the Insurance Commissioner. The purpose of Senate Bill 233 would be to cap costs for insulin.



Fiscal Note Detail


Effect of Proposal Fiscal Year
2021
Increase/Decrease
(use"-")
2022
Increase/Decrease
(use"-")
Fiscal Year
(Upon Full
Implementation)
1. Estmated Total Cost 0 0 0
Personal Services 0 0 0
Current Expenses 0 0 0
Repairs and Alterations 0 0 0
Assets 0 0 0
Other 0 0 0
2. Estimated Total Revenues 0 0 0


Explanation of above estimates (including long-range effect):


Please explain increases and decreases in personal services, current expenses, repairs and alterations, assets, other costs and revenues, including assumptions and data sources and delineation between start-up and ongoing costs. Please also include a long-range schedule of costs and revenues if fiscal impact is expected to vary in future years.



Memorandum


Senate Bill 233 will have no fiscal impact on the operations, expenses or revenues of the Offices of the Insurance Commissioner. Senate Bill 233 seeks to cap the costs of insulin at $100 for a 30 day supply of a covered prescription insulin. With the passage of House Bill 4543 on March 7, 2020 W.Va. Code 33-59-1(e), effective July 1, 2020, already limits cost sharing for a 30-day supply of a covered prescription insulin drug to $100 for a 30-day supply, regardless of the quantity or type of prescription insulin used to fill the covered person's prescription needs.



    Person submitting Fiscal Note: Melinda Kiss
    Email Address: Melinda.A.Kiss@wv.gov